ArticleCancer cell2024
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer.
Abstract read
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer.Cell reports. Medicine · 2025Trial
- Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.Nature reviews. Clinical oncology · 2026Review
- CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Unveiling the role of spatial transcriptomics in the analysis of the tumor immune microenvironment (Review).International journal of molecular medicine · 2026Review
- Subtype-specific mechanisms of lipid metabolism in gynecological malignancies and novel targeted intervention strategies (Review).Oncology letters · 2026Review
- PD-L1 in Ovarian Cancer: Immune Evasion, Tumor-Intrinsic Signaling, and Chemoresistance.Cancer medicine · 2026Review
- Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer.Clinical and translational medicine · 2026Review
- Review
- Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The next generation of antibody-drug conjugates.Nature medicine · 2026Review
- The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.Nature aging · 2026Article
- Macrophage Plasticity in Cancer Therapy: Function, Timing, and Tradeoffs.International journal of molecular sciences · 2026Review
- Transcriptomic analysis of tissue-resident memory T cells of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer prevention.Nature communications · 2026Article
- T Cell Heterogeneity Shaped by Alternative Splicing Predicts Prognosis in Hepatocellular Carcinoma.Cancer science · 2026Article
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- Exhausted CD8⁺ T cells promote ovarian cancer immunosuppression via CCL3-Driven M2 macrophage polarization.Cell death & disease · 2026Article
- Spatial Immunology in Translation: Linking Immune Organisation to Therapeutic Outcome.Medical sciences (Basel, Switzerland) · 2026Review
- Chemotherapy induces an IL1β-dependent neutrophil recruitment and activation that promote chemoresistance in metastatic ovarian cancer.Journal for immunotherapy of cancer · 2026Article
- Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker-Guided Therapeutic Matching.Journal of cellular physiology · 2026Review
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
26 authors.
Inga-Maria LaunonenResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Iga NiemiecResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
María Hincapié-OteroResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Erdogan Pekcan ErkanResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Ada JunqueraResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Daria AfentevaResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Matias M FalcoResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Zhihan LiangResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Matilda SalkoResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Foteini ChamchougiaResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Angela SzaboResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Fernando Perez-VillatoroResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Yilin LiResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Giulia MicoliResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Ashwini NagarajResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Ulla-Maija HaltiaResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland; Department of Obstetrics and Gynecology, Department of Oncology, Clinical Trials Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
Essi KahelinResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland; Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
Jaana OikkonenResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Johanna HynninenDepartment of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland.
Anni VirtanenResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland; Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
Ajit J NirmalLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Tuulia ValliusLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA; Ludwig Center at Harvard, Boston, MA, USA.
Sampsa HautaniemiResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA; Ludwig Center at Harvard, Boston, MA, USA.
Anna VähärautioResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland; Foundation for the Finnish Cancer Institute, Helsinki, Finland. Electronic address: anna.vaharautio@helsinki.fi.
Anniina FärkkiläResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland; Department of Obstetrics and Gynecology, Department of Oncology, Clinical Trials Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland; Institute for Molecular Medicine Finland, Helsinki Institute for Life Sciences, University of Helsinki, Helsinki, Finland. Electronic address: anniina.farkkila@helsinki.fi.
Funding
Integrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial ModelingR00CA256497 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NIRMAL, AJIT JOHNSON · 2023 to 2025
$747kNCI NIH HHS R00 CA256497
Abstract
Anti-tumor immunity is crucial for high-grade serous ovarian cancer (HGSC) prognosis, yet its adaptation upon standard chemotherapy remains poorly understood. Here, we conduct spatial and molecular characterization of 117 HGSC samples collected before and after chemotherapy. Our single-cell and spatial analyses reveal increasingly versatile immune cell states forming spatiotemporally dynamic microcommunities. We describe Myelonets, networks of interconnected myeloid cells that contribute to CD8
Indexed as
CD8-Positive T-LymphocytesMyeloid CellsOvarian NeoplasmsFemaleHumansNectinsSingle-Cell AnalysisT-Cell ExhaustionTumor MicroenvironmentNECTIN2 protein, humanNectinsimmuno-oncologymultiomicsovarian cancerspatial biologytumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.